EDP-323

Enanta Pharmaceuticals will showcase data from its Phase 2 study of zelicapavir in RSV-infected children at the ESPID 2025 meeting, including new findings on PK/PD and viral clearance rates.

Enanta Pharmaceuticals' zelicapavir achieved a significant 0.7 log reduction in peak viral load on Day 9 in a Phase 2 trial for pediatric RSV patients.

Enanta Pharmaceuticals' EDP-323, an investigational RSV inhibitor, demonstrates promising Phase 2a trial results, potentially becoming the first antiviral treatment for RSV infections.

Enanta Pharmaceuticals receives reiterated Buy ratings from JMP Securities and Robert W. Baird, citing promising RSV drug trial results and reduced competition.

Enanta Pharmaceuticals' Zelicapavir (EDP 938) is in Phase II trials (RSVPEDs and RSVHR) targeting RSV in pediatric and high-risk adult populations.